# US Life Sciences BPO Market

> US Life Sciences BPO Market Research Report: Size, Share, Trend Analysis By Service Type (Contract Research, Drug Discovery, Pre-Clinical Trials, Clinical Trials, Medical Writing, Pharmacovigilance, Clinical Data Management, Regulatory Services, Clinical Monitoring) and By Protocol (Development, Site Management) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 13.79%
- **2024:** $ 54.93 Billion
- **2025:** $ 62.5 Billion
- **2035:** $ 227.37 Billion
- **Key Players:** IQVIA (US), Cognizant (US), Labcorp (US), Parexel (US), Charles River Laboratories (US), PRA Health Sciences (US), Syneos Health (US), Wuxi AppTec (CN), Medpace (US)

**Report ID:** MRFR/LS/17863-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-life-sciences-bpo-market-19410

---

## Market Summary

## **US Life Sciences BPO Market Overview**

As per MRFR analysis, the US Life Sciences BPO Market Size was estimated at 56.42 (USD Billion) in 2023. The US Life Sciences BPO Market Industry is expected to grow from 60(USD Billion) in 2024 to 161.2 (USD Billion) by 2035. The US Life Sciences BPO Market CAGR (growth rate) is expected to be around 9.401% during the forecast period (2025 - 2035).

### **Key US Life Sciences BPO Market Trends Highlighted**

The US Life Sciences BPO Market is witnessing several notable trends that reflect the evolving landscape of the industry. One key market driver is the increasing focus on cost efficiency among life sciences companies. By outsourcing non-core functions such as clinical trials, regulatory affairs, and data management, organizations can reduce operational costs while boosting their operational efficiency. Additionally, advancements in technology, particularly in areas like data analytics and artificial intelligence, are reshaping how services are delivered.

These innovations enable better decision-making and improved patient outcomes, making them attractive to US firms.Opportunities abound in the market as well, especially in personalized medicine and therapies. The demand for bespoke solutions is rising, pushing companies to explore partnerships with BPO providers that can support these tailored approaches. Furthermore, the ongoing regulatory changes in the US further amplify the need for specialized services. As firms strive to maintain compliance, the demand for BPO services that can navigate complex regulatory environments continues to grow.

Trends in recent times show a shift towards integrated service models, where life sciences companies seek full-service solutions rather than traditional transactional relationships.This trend is fueled by the necessity for seamless coordination across various stages of drug development and commercialization processes. Moreover, the growing importance of patient-centric approaches in research and drug development is driving life sciences companies to seek BPO partners that understand patient needs and can help engage with them effectively. Overall, the US Life Sciences BPO Market is adapting rapidly to these driving forces, creating a dynamic and collaborative environment in healthcare research and innovation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Life Sciences BPO Market Drivers**

### **Increasing Demand for Outsourcing in Research and Development**

The US Life Sciences Business Process Outsourcing (BPO) Market is experiencing significant growth driven by the increasing demand for outsourcing in Research and Development (R&D) functions by biotech and pharmaceutical companies. As per data from the National Institutes of Health (NIH), the funding for R&D in the biomedical sector has reached approximately USD 50 billion in recent years, highlighting the need for companies to leverage external expertise to maximize project efficiency and reduce time-to-market for novel therapies.Major firms like Pfizer and Johnson & Johnson are increasingly collaborating with specialized service providers to optimize their R&D pipelines.

This strategic move allows them to focus on core competencies while relying on the BPO industry for essential support in clinical trial management, regulatory compliance, and data management services. Consequently, this outsourcing trend is anticipated to sustain the growth trajectory of the US Life Sciences BPO Market Industry, addressing the complexities and costs associated with in-house research efforts.

### **Regulatory Compliance and Cost Efficiency**

One of the pivotal drivers for the US Life Sciences BPO Market is the stringent regulatory environment which necessitates compliance across various phases of product development. The Food and Drug Administration (FDA) has imposed rigorous guidelines that require many companies to invest heavily to ensure they meet these standards.

As a result, organizations are seeking assistance from BPO providers that specialize in regulatory compliance to mitigate the risks of non-compliance fines, which can reach upwards of USD 20 million.This has led to increased partnerships with BPO firms like Covance, who provide necessary expertise in navigating regulations, ultimately allowing companies to save costs while ensuring compliance. The trend toward outsourcing compliance-related tasks will continue to fuel the expansion of the US Life Sciences BPO Market.

### **Technological Advancements in Data Management**

The growth of the US Life Sciences BPO Market is significantly supported by technological advancements in data management and analytics. The increasing volume of healthcare data has prompted organizations to seek advanced capabilities in handling and analyzing large datasets effectively. For instance, Deloitte's report indicates that the healthcare data analytics market is projected to grow to USD 50 billion by 2025.

Companies like IQVIA are investing in innovative data analytics solutions to provide valuable insights and improve decision-making processes for their clients.This continuous evolution in technology enables life sciences companies to outsource data-related functions to BPO providers, which not only enhances efficiency but also supports the precision of research efforts.

### **Rising Demand for Personalized Medicine**

Another driving factor for the growth of the US Life Sciences BPO Market is the increasing demand for personalized medicine. This is underscored by a growing patient preference for treatments that are tailored to individual genetic profiles, drastically shifting pharmaceutical development strategies. According to the American Medical Association, personalized medicine is expected to account for more than 50% of drugs in development by 2030.

Major corporations like Amgen are pivoting their development focus toward customized therapies, requiring specialized services from BPO providers to collect and analyze genetic and clinical data efficiently.As the trend of personalization becomes more pronounced, the need for BPO support is projected to increase, creating significant opportunities within the US Life Sciences BPO Market Industry.

## **US Life Sciences BPO Market Segment Insights**

### **Life Sciences BPO Market Service Type Insights**

The US Life Sciences BPO Market, specifically within the Service Type segment, encompasses a wide range of essential services that cater to the evolving needs of life sciences organizations. This segment plays a pivotal role in facilitating research, development, and operational efficiencies in the field. Contract Research is a prominent component, offering essential expertise that assists organizations in navigating the complexities of clinical trials and regulatory processes. Drug Discovery involves innovative methodologies that significantly contribute to the identification and development of new therapeutics, providing organizations with a competitive edge in the ever-evolving pharmaceutical landscape.

Pre-Clinical Trials represent a critical phase in the development process, where the safety and efficacy of new drugs are rigorously evaluated prior to human trials. Clinical Trials serve as a cornerstone in the life sciences arena, enabling the effective testing of new treatments and therapies, while Medical Writing ensures that comprehensive documentation and reporting standards are met throughout the drug development lifecycle, which is essential for regulatory submissions. Pharmacovigilance, the science related to the detection, assessment, understanding, and prevention of adverse effects, is increasingly crucial in maintaining patient safety and ensuring compliance with government regulations.

Clinical Data Management is vital for ensuring data integrity and validity, providing a framework for the analysis of trial outcomes. Regulatory Services are indispensable for navigating complex approval processes and ensuring that products meet all necessary guidelines before reaching the market. Lastly, Clinical Monitoring ensures that trials are conducted properly and that the data collected is accurate and reliable, which ultimately supports the credibility of the clinical outcomes.

Each of these services plays a significant role in the overall functionality and efficiency of the life sciences industry, underscoring the indispensable nature of the services offered within the US Life Sciences BPO Market segment. As the industry continues to face challenges such as stringent regulations, rising research costs, and the need for real-time data, these services will remain central to driving innovation and ensuring the success of life sciences initiatives in the United States.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Life Sciences BPO Market Protocol Insights**

The Protocol segment of the US Life Sciences BPO Market serves as a vital foundation for the industry, enhancing the efficiency and effectiveness of clinical operations. This segment encompasses key areas such as Development and Site Management, which play essential roles in the research and clinical trial phases. Development focuses on the creation and testing of new drugs and therapies, contributing to the rising demand for innovative solutions in the healthcare sector.

Site Management, on the other hand, ensures that clinical sites operate efficiently, which is crucial for the successful execution of trials.This segment significantly supports compliance with regulations and facilitates rapid patient recruitment, ultimately improving trial timelines. The increasing complexity of clinical studies, alongside the rising need for robust data management, propels the importance of Protocol services. Furthermore, the growing emphasis on patient-centric approaches and the integration of technology like electronic data capture systems enhance Protocol efficiency.

The overall US Life Sciences BPO Market revenue is further driven by these trends, highlighting the significance of the Protocol segment in facilitating advancements in medical science and healthcare delivery.With the market continually evolving, organizations engaged in Protocol will find numerous opportunities for growth as they adapt to changing landscapes and demands within the industry.

## **US Life Sciences BPO Market Key Players and Competitive Insights**

The US Life Sciences BPO Market is characterized by a dynamic landscape where various service providers cater to pharmaceutical, biotechnology, and medical device companies. This market segment is essential for enhancing the operational efficiencies of life sciences organizations, enabling them to focus on core competencies while outsourcing critical functions. The competitive insights reveal a diverse range of players, each with unique strengths and capabilities, contributing to an ecosystem that thrives on innovation, client-centric service offerings, and strategic partnerships.

The increasing demand for cost-effective solutions and improved regulatory compliance has further intensified competition within the market, leading to continuous investments in technology and process improvements that enhance service delivery.

Syneos Health stands out in the competitive environment of the US Life Sciences BPO Market through its integrated biopharmaceutical solutions that encompass both clinical development and commercial services. The company leverages a comprehensive approach, combining its expertise in trial management with a depth of market knowledge that appeals to a variety of life sciences clients. With a strong focus on seamless collaboration, Syneos Health differentiates itself by providing solutions that speed up the drug development process while ensuring compliance with regulatory standards.

Their robust presence in the market is bolstered by a blend of innovative methodologies and tools, which not only enhance operational efficiency but also foster client relationships built on trust and transparency. This unique positioning allows Syneos Health to cater effectively to an evolving industry landscape where agility and customization are paramount.

Cognizant also plays a significant role in the US Life Sciences BPO Market, offering a wide range of services that span clinical, regulatory, and commercial functions. The company is known for its ability to harness advanced technologies, such as artificial intelligence and analytics, to drive efficiency and better decision-making processes. Key products and services include clinical trial management, pharmacovigilance, and regulatory affairs support, enabling clients to navigate the complexities of the life sciences sector efficiently.

Cognizant's market presence is reinforced by strategic mergers and acquisitions that have expanded its capabilities and expertise, positioning it as a formidable competitor in the BPO landscape. Strengths such as a strong technological backbone, industry-specific knowledge, and a commitment to client success further enhance its reputation in the life sciences domain, making Cognizant a key player in shaping the future of the industry. Their ability to adapt to regulatory changes and market demands underscores their significant impact in the US market.

### **Key Companies in the US Life Sciences BPO Market Include**

### **US Life Sciences BPO Market Industry Developments**

Recent news developments in the US Life Sciences BPO Market have highlighted significant activity among key players. Notably, Syneos Health has continued to expand its portfolio by enhancing service capabilities, reflecting a growing demand for specialized solutions in the sector. Cognizant recently announced a partnership to boost digital solutions for life sciences companies, indicating a trend towards innovation in operations. In terms of mergers and acquisitions, Medpace acquired a smaller clinical research organization in August 2023, aiming to broaden its geographical footprint and service offerings, which adds competitive strength in the market.

Veristat’s recent investment in advanced technologies further underscores the focus on improving efficiency and effectiveness in drug development processes. The life sciences BPO market is experiencing notable growth, with firms like Catalent and IQVIA projecting increased revenues through strategic alliances and technological advancements. Moreover, the US government is also actively supporting the life sciences sector through initiatives aimed at enhancing healthcare services, as seen in the ongoing reforms since 2021 to streamline research processes. This combination of partnerships, acquisitions, and governmental support indicates a robust environment for growth within the US Life Sciences BPO sector.

## **US Life Sciences BPO Market Segmentation Insights**

### **Life Sciences BPO Market Service Type Outlook**

### **Life Sciences BPO Market Protocol Outlook**

## Market Drivers

### Increased Regulatory Scrutiny

The life sciences-bpo market is significantly influenced by heightened regulatory scrutiny across the industry. Regulatory bodies are imposing stricter guidelines and compliance requirements, compelling life sciences companies to enhance their operational frameworks. This has led to a surge in demand for BPO services that specialize in compliance management, quality assurance, and regulatory submissions. The market is projected to grow as organizations seek to mitigate risks associated with non-compliance, which can result in substantial financial penalties. It is estimated that non-compliance can cost companies up to 10% of their annual revenue, underscoring the critical role of BPO providers in ensuring adherence to regulatory standards within the life sciences sector.

### Focus on Patient-Centric Services

The life sciences-bpo market is evolving towards a more patient-centric approach, reflecting a broader trend within the healthcare sector. Companies are increasingly prioritizing patient engagement and personalized services, which necessitates the expertise of BPO providers. This shift is driven by the growing demand for tailored healthcare solutions and the need for improved patient outcomes. As a result, BPO services that focus on patient support, adherence programs, and real-world evidence generation are gaining traction. The market is likely to see a growth rate of around 7% as organizations recognize the value of enhancing patient experiences through specialized outsourcing solutions in the life sciences sector.

### Expansion of Biopharmaceutical Sector

The life sciences-bpo market is benefiting from the rapid expansion of the biopharmaceutical sector, which is becoming a dominant force within the healthcare landscape. As biopharmaceutical companies scale their operations, they increasingly rely on BPO services to manage complex processes such as clinical trials, regulatory submissions, and post-market surveillance. The biopharmaceutical market is projected to reach $500 billion by 2026, creating substantial opportunities for BPO providers. This growth is likely to drive demand for specialized services that cater to the unique needs of biopharmaceutical companies, thereby enhancing the overall landscape of the life sciences-bpo market.

### Rising Demand for Outsourced Services

The life sciences-bpo market is experiencing a notable increase in demand for outsourced services, driven by the need for cost efficiency and operational flexibility. Companies in the life sciences sector are increasingly recognizing the benefits of outsourcing non-core functions such as clinical trials, data management, and regulatory affairs. This trend is reflected in the market's projected growth rate of approximately 8.5% annually, indicating a robust shift towards outsourcing. As organizations seek to streamline operations and focus on core competencies, the life sciences-bpo market is positioned to capture a larger share of the overall life sciences industry. The financial implications are significant, with companies potentially saving up to 30% on operational costs by leveraging specialized service providers.

### Technological Integration and Innovation

The life sciences-bpo market is witnessing a transformative phase characterized by technological integration and innovation. The adoption of advanced technologies such as artificial intelligence, machine learning, and big data analytics is reshaping service delivery models. These technologies enable BPO providers to offer more efficient and accurate services, enhancing data management and patient engagement. The market is expected to expand as companies increasingly invest in technology-driven solutions to improve operational efficiency. It is projected that by 2026, the integration of these technologies could lead to a 20% reduction in time-to-market for new drugs, highlighting the potential impact on the life sciences industry.

## Future Outlook

The [Life Sciences BPO Market](https://www.marketresearchfuture.com/reports/life-sciences-bpo-market-10167) is projected to grow at a 13.79% CAGR from 2025 to 2035, driven by technological advancements, increasing outsourcing, and regulatory complexities.

**New opportunities:**

- Development of AI-driven data analytics platforms for clinical trials. Expansion of remote patient monitoring services to enhance patient engagement. Implementation of blockchain technology for secure data management in research.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Service Type: Clinical Trials (Largest) vs. Drug Discovery (Fastest-Growing)

The US life sciences-bpo market showcases a diverse service type landscape, with Clinical Trials holding the largest share. Other significant segments include Drug Discovery and Regulatory Services, each contributing notably to the overall distribution. As companies continue to outsource non-core functions, the emphasis on specialized services like Clinical Data Management is also growing, reflecting shifting priorities in the healthcare ecosystem.

Growth trends in this segment are driven by advancements in technology and an increasing emphasis on patient-centric approaches. The rising complexity of drug development processes necessitates effective management of Clinical Trials and Pharmacovigilance, creating a higher demand for these services. Additionally, innovation in medical writing and regulatory compliance is gradually reshaping service delivery, further accelerating market progression.

Clinical Trials: Dominant vs. Drug Discovery: Emerging

Clinical Trials are recognized as the dominant service type in the US life sciences-bpo market, characterized by their extensive scope and critical role in the drug development process. They encompass various phases, from initial testing to final approvals, making them indispensable for pharma companies. On the other hand, Drug Discovery is emerging rapidly, fueled by technological advancements and the need for faster drug development cycles. This segment leverages cutting-edge research and data analytics to streamline the drug discovery process, helping biopharmaceutical firms innovate therapeutics efficiently. The contrast between these segments highlights a dynamic market where traditional strongholds are being challenged by innovative approaches to drug development.

### By Protocol: Development (Largest) vs. Site Management (Fastest-Growing)

In the US life sciences-bpo market, Development is a significant segment, holding the largest market share among protocol-related services. This segment encompasses various activities involved in drug development and clinical trials, which are critical to bringing new therapies to market. On the other hand, Site Management is gaining traction as an emerging segment. It focuses on managing clinical trial sites effectively, ensuring compliance, and optimizing operations. Over time, Site Management has seen increasing investments and interest, reflecting the growing complexities of trial execution.

The growth trends in these segments are driven by the rising demand for more efficient and effective drug development processes. As pharmaceutical companies aim to shorten time-to-market for new treatments, Development services are imperative in meeting these goals. Meanwhile, Site Management is becoming essential due to the need for improved site performance and patient recruitment strategies, highlighting the increasing importance of operational excellence in clinical trials.

Development (Dominant) vs. Site Management (Emerging)

Development remains the dominant force within the protocol segment of the US life sciences-bpo market, characterized by its extensive array of services ranging from initial research to late-stage clinical trials. This segment plays a crucial role in facilitating innovation and speeding up the availability of groundbreaking therapies to patients. In contrast, Site Management is an emerging player that is rapidly gaining importance due to the complexities of conducting clinical trials in diverse environments. This segment focuses on optimizing site operations to enhance performance, ensure compliance, and improve patient engagement. As companies turn their attention to efficiency and effectiveness, Site Management is positioned to grow considerably, driven by the need for refined processes and strategies in clinical research.

## Competitive Benchmarking

The life sciences-bpo market is characterized by a dynamic competitive landscape, driven by the increasing demand for outsourcing services in research, development, and commercialization of pharmaceuticals and biotechnology products. Key players such as IQVIA (US), Cognizant (US), and Labcorp (US) are strategically positioned to leverage their extensive expertise and technological capabilities. For instance, IQVIA (US) focuses on integrating advanced analytics and real-world data to enhance clinical trial efficiency, while Cognizant (US) emphasizes digital transformation and automation to streamline operations. Labcorp (US) is enhancing its service offerings through strategic partnerships, thereby shaping a competitive environment that prioritizes innovation and operational excellence.The market structure appears moderately fragmented, with a mix of large multinational corporations and specialized firms. Key players are employing various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance their competitive edge. This collective influence of major companies fosters a competitive atmosphere where agility and responsiveness to market needs are paramount.
In October Cognizant (US) announced a strategic partnership with a leading biotech firm to develop AI-driven solutions for drug discovery. This collaboration is expected to significantly accelerate the drug development process, showcasing Cognizant's commitment to integrating cutting-edge technology into its service offerings. The strategic importance of this partnership lies in its potential to enhance the efficiency of research and development, thereby positioning Cognizant as a leader in innovation within the life sciences-bpo market.
In September Labcorp (US) expanded its global footprint by acquiring a European clinical research organization. This acquisition is likely to enhance Labcorp's capabilities in conducting clinical trials across diverse populations, thereby improving the quality and speed of data collection. The strategic significance of this move is underscored by the growing need for global clinical trial services, which are essential for meeting regulatory requirements and ensuring patient diversity in research.
In August Parexel (US) launched a new digital platform aimed at improving patient engagement in clinical trials. This initiative reflects Parexel's focus on enhancing the patient experience and increasing recruitment efficiency. The strategic importance of this platform lies in its ability to leverage technology to address one of the critical challenges in clinical research—patient retention and engagement, which are vital for successful trial outcomes.
As of November current trends in the life sciences-bpo market indicate a strong emphasis on digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and adapt to evolving market demands, underscoring the importance of agility and strategic foresight in this rapidly changing environment.

## Recent News & Developments

Recent news developments in the US Life Sciences BPO Market have highlighted significant activity among key players. Notably, Syneos Health has continued to expand its portfolio by enhancing service capabilities, reflecting a growing demand for specialized solutions in the sector. Cognizant recently announced a partnership to boost digital solutions for life sciences companies, indicating a trend towards innovation in operations. In terms of mergers and acquisitions, Medpace acquired a smaller clinical research organization in August 2023, aiming to broaden its geographical footprint and service offerings, which adds competitive strength in the market.

Veristat’s recent investment in advanced technologies further underscores the focus on improving efficiency and effectiveness in drug development processes. The life sciences BPO market is experiencing notable growth, with firms like Catalent and IQVIA projecting increased revenues through strategic alliances and technological advancements. Moreover, the US government is also actively supporting the life sciences sector through initiatives aimed at enhancing healthcare services, as seen in the ongoing reforms since 2021 to streamline research processes. This combination of partnerships, acquisitions, and governmental support indicates a robust environment for growth within the US Life Sciences BPO Market sector.

## Report Scope

| MARKET SIZE 2024 | 54.93(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 62.5(USD Billion) |
| MARKET SIZE 2035 | 227.37(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.79% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | IQVIA (US), Cognizant (US), Labcorp (US), Parexel (US), Charles River Laboratories (US), PRA Health Sciences (US), Syneos Health (US), Wuxi AppTec (CN), Medpace (US) |
| Segments Covered | Service Type, Protocol |
| Key Market Opportunities | Integration of advanced analytics and artificial intelligence in the life sciences-bpo market enhances operational efficiency. |
| Key Market Dynamics | Growing demand for outsourcing in Research and Development drives innovation and efficiency in the life sciences-bpo market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US life sciences-bpo market in 2024?**
A: The overall market valuation was $54.93 Billion in 2024.

**Q: What is the projected market valuation for the US life sciences-bpo market by 2035?**
A: The projected valuation for 2035 is $227.37 Billion.

**Q: What is the expected CAGR for the US life sciences-bpo market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 13.79%.

**Q: Which segment had the highest valuation in 2024 within the US life sciences-bpo market?**
A: The Clinical Trials segment had the highest valuation at $12.0 Billion in 2024.

**Q: What is the projected valuation for the Drug Discovery segment by 2035?**
A: The projected valuation for the Drug Discovery segment is $34.0 Billion by 2035.

**Q: Which company is recognized as a key player in the US life sciences-bpo market?**
A: IQVIA is recognized as a key player in the US life sciences-bpo market.

**Q: What was the valuation of the Clinical Data Management segment in 2024?**
A: The Clinical Data Management segment was valued at $6.0 Billion in 2024.

**Q: What is the projected growth for the Pharmacovigilance segment by 2035?**
A: The Pharmacovigilance segment is projected to grow to $12.0 Billion by 2035.

**Q: How much was the Pre-Clinical Trials segment valued at in 2024?**
A: The Pre-Clinical Trials segment was valued at $5.0 Billion in 2024.

**Q: What is the expected valuation for the Site Management segment by 2035?**
A: The expected valuation for the Site Management segment is $142.37 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-life-sciences-bpo-market-19410*